<DOC>
	<DOCNO>NCT00827307</DOCNO>
	<brief_summary>The purpose study compare Zoladex plus tamoxifen tamoxifen alone adjuvant hormonal therapy pre- perimenopausal woman early-stage breast cancer term breast density , estrogen level , lipidemia , endometrial thickness ultrasonographic abnormality .</brief_summary>
	<brief_title>Zoladex Plus Tamoxifen Breast Cancer</brief_title>
	<detailed_description>After completion primary treatment ( surgery and/or adjuvant chemotherapy , radiotherapy could give concurrently study medication ) , eligible patient randomize receive Zoladex plus tamoxifen tamoxifen alone . The duration study medication along follow-up 18 month , disease recurrence , discontinuation study therapy ( result adverse event , patient 's request , investigator 's decision ) , treatment investigator 's discretion . During study period , contralateral mammogram transvaginal ultrasound undertaken baseline 6 , 12 18 month study medication . Mammographic density assessment undertaken single radiologist . Serum measurement include estrogen level lipidemia obtain baseline 3 , 6 , 12 18 month study medication .</detailed_description>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>provision inform consent histologically proven HR+ operable invasive breast cancer completion surgery chemotherapy ( give ) . woman define pre perimenopausal accord follow : age 50 year young , least one menstrual period last month . clinical evidence metastatic disease pregnancy breastfeed bilateral oophorectomy ; radiation ovaries patient , whatever reason ( eg , confusion , infirmity , alcoholism ) , unlikely comply trial requirement patient whose chemotherapy start 8 week completion primary surgery whose chemotherapy complete 8 week start study treatment . Chemotherapy , give , give postoperatively , ie , patient receive neoadjuvant chemotherapy ineligible patient receive chemotherapy whose primary surgery complete 8 week start study treatment previous hormonal therapy adjuvant treatment breast cancer patient unwilling stop take drug know affect sex hormonal status , would inappropriate stop previous history invasive malignancy within last 5 year , squamous basal cell carcinoma skin carcinoma situ cervix , adequately cone biopsied treatment nonapproved experimental drug 1 month entry study history hypersensitivity active inactive excipients tamoxifen Zoladex history bleed diathesis ( ie . Disseminated intravascular coagulation , clot factor deficiency ) , long term anticoagulant therapy ( antiplatelet therapy low dose warfarin ) leukopenia and/or thrombocytopenia history ocular fundus disease history thromboembolic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>breast carcinoma ; goserelin ; Mammographic density</keyword>
</DOC>